PATNA: The ICMR has shortlisted AIIMS-Patna among 12 institutes for conducting clinical trials of indigenous Covid-19 vaccine BBV152 developed by Hyderabad-based Bharat Biotech in collaboration with National Institute of Virology (NIV), Pune.
ICMR director general Dr Balram Bhargava has written a letter to the 12 shortlisted institutes, informing them about the development.
On being asked, AIIMS-P director Prabhat Kumar Singh told TOI on Saturday that the process of clinical trials is at the preliminary stage. “A decision on commencement of trials will be taken after several rounds of meetings and discussions,” he said.
Dr Neeraj Aggarwal, the nodal officer for Covid-19 and dean of AIIMS-P, said: “Our main concern right now is to finalise the procedure and successfully conduct the trials. It is a very critical step as the country’s hope depends on its success or failure.”
ICMR director general Dr Balram Bhargava has written a letter to the 12 shortlisted institutes, informing them about the development.
On being asked, AIIMS-P director Prabhat Kumar Singh told TOI on Saturday that the process of clinical trials is at the preliminary stage. “A decision on commencement of trials will be taken after several rounds of meetings and discussions,” he said.
Dr Neeraj Aggarwal, the nodal officer for Covid-19 and dean of AIIMS-P, said: “Our main concern right now is to finalise the procedure and successfully conduct the trials. It is a very critical step as the country’s hope depends on its success or failure.”
